|
Canada-0-Liquidators Azienda Directories
|
Azienda News:
- Rechallenge therapy versus tyrosine kinase inhibitor (TKI . . .
Abstract Currently, the standard third-line treatment options for advanced metastatic colorectal cancer (mCRC) include regorafenib, fruquintinib, and trifluridine tipiracil (TAS-102), but these drugs have limited clinical efficacy This study aims to evaluate the efficacy and survival outcomes of tyrosine kinase inhibitor (TKI) versus chemotherapy rechallenge in third-line treatment for
- Lost in translation: Revisiting the use of tyrosine kinase . . .
Patients with advanced or metastatic colorectal cancer ( (m)CRC) have limited effective treatment options resulting in high mortality rates A better understanding of the molecular basis of this disease has led to growing interest in small molecule tyrosine kinase inhibitors (TKIs) for its treatment
- Zanzalintinib Atezolizumab Improves CRC Survival, Expands TKI . . .
New trial results reveal zanzalintinib and atezolizumab significantly enhance survival in metastatic colorectal cancer, marking a breakthrough in treatment options
- High-dose short-term osimertinib treatment is effective in . . .
Most tyrosine kinase inhibitors (TKIs) have failed in clinical trials for metastatic colorectal cancer (mCRC) To leverage the additional lower-affinity targets that most TKIs have, high-dose
- Exploring research frontiers and emerging trends of tyrosine . . .
Background Tyrosine kinase inhibitors (TKIs) are a class of molecular targeted drugs designed to selectively inhibit tyrosine kinase activity associated with oncogenic signaling pathways and drivers, and have emerged as key therapeutic agents for colorectal cancer (CRC) The purpose of this study is to explore the research status and development trend of TKIs in CRC treatment Methods The Web
- Multi-omics characterization of response to tyrosine kinase . . .
Multi-omics characterization of response to tyrosine kinase inhibitor plus immunotherapy in MSS pMMR metastatic colorectal cancer: A multicenter biomarker study If you have the appropriate software installed, you can download article citation data to the citation manager of your choice
- Fruquintinib as new treatment option in metastatic colorectal . . .
Introduction Available treatments for colorectal cancer are limited However, in the last few years several advances and new treatment options became available and expanded the continuum of care in metastatic colorectal cancer (mCRC)
- Frontiers | A multi-center effectiveness comparison study of . . .
A multi-center effectiveness comparison study of fruquintinib with constructed external control cohort of other targeted kinase inhibitors using real-world data in third-line treatment of metastatic colorectal cancer
- RETRACTED ARTICLE: Rechallenge therapy versus tyrosine kinase . . .
Currently, the standard third-line treatment options for advanced metastatic colorectal cancer (mCRC) include regorafenib, fruquintinib, and trifluridine tipiracil (TAS-102), but these drugs have limited clinical efficacy
- A Digital Twin of RAS Wildtype Metastatic Colorectal Cancer . . .
DT cohorts of metastatic colorectal cancer (mCRC) patients can serve as virtual standard-of-care (SOC) arms for reducing time, cost, and effort We evaluated the feasibility of constructing a DT cohort of left-sided RAS wild-type mCRC and assessed the efficacy of SOC
|
|